Under the category of the OTC/Nutraceutical products are listed the products which are sold without prescription. Members of Farmavita.net are invited to publish their out-license offers in this Category.


Misoprostol -  New Indications

Member of Farmavita.net is offering dossier in European CTD format for Misoprostol, 100 - 200 mcg, tablets.

Dossier is submitted in reference member state. License for use of Dossier is related to initial downpayment and commitment to bulk purchase.  

Misoprostol is classified as an alimentary tract and metabolism medicine, according ATC index.

Misoprostol was previously approved for reducing the risk of NSAID-induced gastric ulcers in patients at high risk of complications from gastric ulcer and for medical abortion (

  • Prevention of PPH
  • Cervical ripening
    • Cervical ripening prior to uterine instrumentation
    • Cervical ripening for induction of labour in live foetus
    • Cervical ripening for induction of labour in intrauterine foetal death.

Dosage and method of administration is as follows:
For Prevention of Post Partum Haemorrhage

For prevention of post partum haemorrhage - 600 µg misoprostol orally immediately after cord clamping.

 For Cervical Ripening

Cervical ripening prior to uterine instrumentation
Dosage: 400 µg misoprostol vaginally, 2-3 hours before the procedure.

Cervical ripening for induction of labour (live baby >28 weeks)
Dosage: 25 µg misoprostol vaginally, every 3- 4 hours until contractions

Maximum: Six doses

Should be used in institutions that are able to perform caesarean sections. Foetal well-being and uterine contractions should be monitored. Beware of uterine hyperstimulation with the risk of uterine rupture and foetal distress.

Cervical ripening for induction of labour (intrauterine foetal death >28 weeks)
Dosage: 50 µg misoprostol vaginally, every 3-4 hours until delivery

Maximum: Six doses.

Offer is valid subject to confirmation, country by country. Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 109

Advertiser details

Contact Advertiser

Add comment


Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

Adalimumab API available: - from EU cGMP...
Start-up pharmaceutical company from South...
Member of Farmavita.net is looking to...
I want to give process knowhow and NON GMO...
 Company portfolio: Manufacturing over 100...
Objective: To enter into EU domain procuring...